Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 532Gastro-enteropancreatic neuroendocrine tumor 58Carcinoid Tumor 58Neoplasms 49Carcinoma, Neuroendocrine 44Pancreatic Neoplasms 36Adenoma, Islet Cell 33Neoplasm Metastasis 28Pheochromocytoma 26Paraganglioma 24Colorectal Neoplasms 24Stomach Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Lung Neoplasms 20Carcinoma, Hepatocellular 20Sarcoma 19Carcinoma 19Thyroid Neoplasms 18Gastrointestinal Neoplasms 18Neuroblastoma 15Cholangiocarcinoma 14Carcinoma, Renal Cell 14Small Cell Lung Carcinoma 13Melanoma 13Esophageal Neoplasms 13Serotonin Syndrome 12Colonic Neoplasms 12Brain Neoplasms 11Adenocarcinoma 11

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metatropic dwarfism × NET × Clear all
NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

King Faisal Specialist Hospital & Research Center

Phase 1/2 Unknown
30 enrolled
EndocrineNET

Metatropic dwarfism, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡